Utilidad del test aptima en el diagnóstico de las lesiones precancerígenas del cérvixcomparación de Aptima con otros test diagnósticos

  1. M.P. Cano
  2. A. Sáez
  3. I. Romero
  4. José Manuel Bajo Arenas
  5. J. Valero de Bernabé
Revue:
Toko-ginecología práctica

ISSN: 0040-8867

Année de publication: 2017

Número: 753

Pages: 127-133

Type: Article

DIALNET GOOGLE SCHOLAR

D'autres publications dans: Toko-ginecología práctica

Résumé

Objetivos: Este estudio pretende evaluar la utilidad del test APTIMA, que identifica mRNA E6/E7 de 14 tipos de virus del papiloma humano de alto riesgo (HPV-AR), para el diagnóstico de neoplasias intraepiteliales cervicales (CIN) grado 2 o peor, así como comparar la sensibilidad de dicho test con otros test diagnósticos. Material y métodos: Un total de 203 pacientes, referidas a colposcopia por presentar una citología anómala o un test positivo para HPV-AR, fueron evaluadas con APTIMA, Hybrid Capture (HC2), Cobas 4800, Linear Array y tinción inmunohistoquímica p16INK4a. Resultados: Se calculó la sensibilidad para todos los test teniendo como endpoint CIN2+ y CIN3+, encontrando cifras de sensibilidad superiores al 90% para todos ellos. La sensibilidad para APTIMA fue 92.80% y 92.94% para CIN2+ y CIN3+ respectivamente (p<0.0001), la de HC2 96.80% y 95.29% (p<0.0001), la de Cobas 4800 96.00% y 95.29% (p=0.011), la de Linear Array 98.40% y 97.65% (p=0.007) y la de p16INK4a 95.90% y 96.39% (p<0.0001). El test APTIMA y la tinción imnunohistoquímica p16INK4a presentaron los mejores valores de especificidad, 35.90% y 47.94%, respectivamente (p<0.0001). Conclusión: APTIMA tiene una sensibilidad similar a otros test diagnósticos para la detección de CIN2+, por lo que podría ser un test útil para el screening del cáncer de cérvix.

Références bibliographiques

  • Horner MJ, Ries LAG, Krapcho M. SEER Cancer Statistics Review 1975-2006. National Cancer Institute. 2009.
  • World Health Organization International Agency for Research on Cancer. GLOBOCAN database 2002. CANCER Mondial. 2002.
  • Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189 (1):12-19.
  • Zur Hausen H. Papillomaviruses and cancer: from basics studies to clinical application. Nat Rev Cancer. 2002;2(5);342-350.
  • Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cáncer-burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
  • Muñoz N, BoschFX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
  • Sant M, Allemani C, Santaquilani M, Arnold K, Marchesi F, Capocaccia R, et al. EUROCARE-4. Survival of cáncer patientes diagnosed in 1995- 1999. Results and commentary. Eur J Cancer. 2009;45:931-91.
  • Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur j Cancer 2009;45:1042-66.
  • Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189 (1):12-19.
  • Nakagawa S, Yoshikawa H, Yasugi T, Kimura M, Kawana K, Matsumoto K, et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J Med Virol. 2000;62(2):251-8.
  • Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33 and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006;44(4):1310-7.
  • Varela Lema L, Queiro Verdes T. Detección de los oncogenes E6/E7 para el diagnóstico precoz de cáncer de cuello de útero. Santiago de Compostela: Consellería de Sanidade, Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia, avalia-t; 2010. Serie Avaliación de Tecnoloxías. Consultas técnicas: CT2010/01.
  • Castle PE, Dockter J, Giachetti C, García F, et al. A cross-sectional Study of a Prototype Carcinogenic Human Papillomavirus E6/E7 Messenger RNA Assay for Detection of Cervical Precancer and Cancer. Clin Cancer Res. 2007;13:2599-2605.
  • Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J CLin Virol. 2009;45:55-61.
  • Szarewski A, Laurence A, Cadman L, Austin J, Ho L, et al. Comparison of Predictors for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3033-42.
  • Rijkaart DC, Coupe VM, van Kemenade FJ, Heideman DA, Hasselink AT, Verweij W, et al. Comparison of hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer. 2010;103:939-46.
  • Carreon JD, Sherman ME, Guillen D et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26:441-6.
  • Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, et al. Aptima HPV E6/E7 mRNA Test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol. 2011;49:557-564.
  • Szarewski A, Mesher D, Cadman L, Austin J, Adhdow-Barr L, et al. Comparison of Seven Test for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study. J Clin Microbiol. 2012;50:1867-1873.
  • Waldstrom M, Ornskov D. Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US). Cytopathology. 2010;23:389-395.
  • Stoler MH, Thomas C, Wright Jr MD, Cuzick J, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol. 2013;208:144.e1-8.
  • Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, et al. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage with ASC-US or LSIL cervical cytology: A metaanalysis of the diagnostic accuracy. Int J Cancer. 2013;132:101-108.
  • Mesher D, Szarewski A, Cadman L, Austin J, Ashdow-Barr L et al. Comparison of human Papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. European Journal of Cancer. 2013;49:2179-2186.
  • Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, et al. Comparing the performance of six human Papillomavirus test in a screening population. British Journal of Cancer. 2013;8:908-913.
  • Monsonego J, Hudgens MG, Zerat L, Zerat JC, et al. Evaluation of oncogenic human Papillomavirus RNA and DNA test with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;129:691-701.
  • Monsonego J, Hudgens MG, Zerat L, Zerat JC et al. Risk assessment and clinical impact of liquidbased cytology, oncogenic human Papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study). Gynecologic Oncology. 2012;125:175-180.
  • Wu R, Belinson SE, Du H, Na W, et al. Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening, The Shenzen Cervical Cancer Screening Trial I. Int J Gynecol Cancer. 2010;8:1411-14.
  • Clad A, Reuschenbach M, Weinschenk J, et al. Performance of the Aptima High-Risk Human Papillomavirus mRNA Assay in a Referral Population in Comparison with Hybrid Capture 2 and Cytology. J Clin Microbiol. 2011;49(3):1071-1076.
  • Cuschieri K, Whitley M, Cubie H. Human Papillomavirus type specific DNA and RNA persistence: implications for cervical disease progression and monitoring. J Med Virol. 2004;73:65-70.
La source de données: Dialnet